Pelthos Targets Xepi Promotion to Current Customers by End of Q1 2027

Pelthos Therapeutics Inc. Chief Commercial Officer Sai Rangarao set an end-of-Q1 2027 target for beginning Xepi promotion to the company’s current customer base, as Pelthos pursues a proposed merger with Castle Creek Biosciences.

Rangarao outlined the timing on Nov. 12. Pelthos also has a separate target to launch Xepi in Q1 2027; the promotion plan specifically covers its current customer base.

The plan follows Pelthos’ third-quarter results, when net product revenue from Zelsuvmi rose 114% from a year earlier to $15.2 million.

Pelthos expects the proposed merger with Castle Creek to close by the end of Q1 2027, subject to approval from Castle Creek stockholders and other customary closing conditions.